Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name

DrugBank Accession Number

DB10791

Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Vaccines
Inactivated

Synonyms

Not Available

Pharmacology

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)	hemagglutinin	C8E791RO82	Not Available	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2011-07-01	2012-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2010-07-23	2011-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2013-06-28	2014-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Physicians Total Care, Inc.	2010-09-16	2011-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza B virus B/Texas/6/2011 antigen (formaldehyde inactivated) (7.5 ug/0.25mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2012-07-02	2013-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2011-07-01	2012-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2010-07-23	2011-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2013-06-28	2014-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (9 ug/0.1mL) + Influenza B virus B/Massachusetts/2/2012 antigen (formaldehyde inactivated) (9 ug/0.1mL)	Injection, suspension	Intradermal	Sanofi Pasteur Limited	2013-06-28	2014-06-30
Fluzone	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) (15 ug/0.5mL)	Injection, suspension	Intramuscular	Sanofi Pasteur Limited	2014-06-27	2015-06-30

Chemical Identifiers

UNII: XQO8062U6R
CAS number: Not Available

References

General References: Not Available
External Links: Not Available

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Adverse Drug Reaction (ADR) / Injection Site Reactions / Pain / Quality of Life (QOL)	1
4	Active Not Recruiting	Prevention	Coronavirus Disease 2019 (COVID‑19) / Influenza, Human	1
4	Active Not Recruiting	Prevention	Plasma Cell Neoplasms	1
4	Completed	Basic Science	Cytomegalovirus (CMV) Infection / Flu caused by Influenza	1
4	Completed	Basic Science	Flu caused by Influenza	14
4	Completed	Basic Science	Flu Vaccine	1
4	Completed	Basic Science	Immune Response to Influenza Vaccine / Influenza A Virus Infection / Influenza B Virus Infection	1
4	Completed	Basic Science	Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)	1
4	Completed	Basic Science	Rheumatoid Arthritis	1
4	Completed	Health Services Research	Healthy Subjects (HS)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, suspension	Intramuscular
Injection, suspension	Intradermal
Kit	Topical

Prices

Not Available

Patents

Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Drug created at December 01, 2015 20:04 / Updated at June 12, 2020 16:53

Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)

Identification

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties